On July 19, 2019, Sichuan International Medical Exchange & Promotion Association (SCIMEA) opened a preparatory meeting for establishment of a Professional Thyroid Tumor Committee (PTCC). Specialists from multiple institutions were present, including SCIMEA Secretary General Zhang Mengfan, PTCC founder, Professor Zhu Jingqiang from the Thyroid Surgery of West China Hospital of Sichuan University, Professor Huang Rui from the Nuclear Medicine Department of West China Hospital of Sichuan University, Professor Shi Hubing from the State Key Laboratory of Biotherapy of Sichuan University, Chief Physician Wu Jian of the Third People's Hospital of Chengdu, Professor Zhao Xiaobo from the Affiliated Hospital of North Sichuan Medical College, Professor Zhou Xiangyu from the Affiliated Hospital of Southwest Medical University, and Luo Han from West China Hospital of Sichuan University.

Speech by SCIMEA Secretary General Zhang Mengfan

SCIMEA Secretary General Zhang Mengfan introduced the basic situation of the Association, elaborated on its development path and specific planning, stressed the thoughts about diversified development of SCIMEA. He hoped that forming a professional committee for thyroid cancer could promote the exchanges and interactions in this field across Sichuan province, China and the rest part of the world and drive overall development.

Speech by Professor Zhu Jingqiang, PTCC Founder

Professor Zhu Jingqiang introduced the preparation, forming plan and work objective of PTCC, and emphasized that the advancement of thyroid tumor specialty is an important task in the medical domain and therefore we should vigorously promote international medical exchanges to fully learn from and absorb the achievements in new medical science and technology at home and abroad, further improving thyroid cancer medicine. He hoped that SCIMEA, as a platform, could link manufacturers, enterprises, and governments in an all-round way to reinforce scientific research and increase the international recognition of the province’s thyroid cancer medicine.

The members of the preparatory group discussed the forming issues of the new committee and reached a consensus to the leadership structure, member selection, regional member distribution plan, and other issues regarding committee forming in accordance with the Bylaws of SCIMEA and the requirements for the setup of the committee. An inaugural meeting is initially set in November, 2019 to complete the preparatory work.